Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carcinoid tumors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Carcinoid tumors. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-004507-18 Sponsor Protocol Number: CRAD001C2325 Start Date*: 2007-01-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or Sandostatin LAR® Depot a...
    Medical condition: Low grade neuroendocrine carcinoma consists of carcinoid and pancreatic endocrine tumors. These tumors originate from the neuroendocrine cells throughout the body and are capable of producing vario...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007276 Carcinoid tumour NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) FR (Completed) BE (Completed) SK (Completed) DE (Completed) ES (Completed) NL (Completed) GB (Completed) GR (Completed) IT (Completed) FI (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013222-16 Sponsor Protocol Number: 8-55-52060-004 Start Date*: 2009-12-02
    Sponsor Name:Ipsen Pharma
    Full Title: Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with ca...
    Medical condition: carcinoid syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.0 10007270 Carcinoid syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) IE (Completed) ES (Prematurely Ended) BE (Completed) AT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) SK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002596-18 Sponsor Protocol Number: LX1606.1-302-CS Start Date*: 2013-12-17
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
    Medical condition: Carcinoid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) SE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006514-42 Sponsor Protocol Number: A-99-52030-216 Start Date*: 2008-01-23
    Sponsor Name:Institut Produits Synthèse (IPSEN) AB
    Full Title: A PHASE IV, OPEN-LABEL, RANDOMISED, CROSS-OVER STUDY TO ASSESS PATIENT PREFERENCE AND HEALTH ECONOMY IN PATIENTS WITH NEUROENDOCRINE TUMOURS, TREATED WITH LANREOTIDE AUTOGEL GIVEN AS SELF ADMINISTR...
    Medical condition: Symptoms associated with carcinoid syndrome in patients with neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007270 Carcinoid syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016973-13 Sponsor Protocol Number: LX1606.1-203-CS Start Date*: 2010-03-08
    Sponsor Name:Lexicon Pharmaceuticals, Inc
    Full Title: A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome
    Medical condition: Symptomatic Carcinoid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    15.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000739-25 Sponsor Protocol Number: CSOM230C2303 Start Date*: 2008-01-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately contr...
    Medical condition: Metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007271 Carcinoid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) DE (Completed) IT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) BE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003460-47 Sponsor Protocol Number: LX1606.1-301-CS Start Date*: 2012-12-19
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome N...
    Medical condition: refractory carcinoid syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) IT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000762-18 Sponsor Protocol Number: CRN00808-11 Start Date*: 2023-01-24
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.
    Medical condition: Carcinoid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001543-31 Sponsor Protocol Number: LX1606.1-303-CS Start Date*: 2014-02-17
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome
    Medical condition: Carcinoid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) SE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019066-92 Sponsor Protocol Number: 2-55-52030-730/TR321 Start Date*: 2010-08-31
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A double-blind, randomized placebo-controlled clinical trial investigating the efficacy and safety of Somatuline Depot (lanreotide) Injection in the treatment of carcinoid syndrome
    Medical condition: Carcinoid syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005049-11 Sponsor Protocol Number: AAA-III-01 Start Date*: 2012-04-25
    Sponsor Name:Advanced Accelerator Applications
    Full Title: A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperabl...
    Medical condition: Patients with inoperable, progressive, OctreoScan® positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours), who are treated with 20 mg or 30 mg Octreotide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062392 Carcinoid tumor of the small bowel LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) PT (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016716-20 Sponsor Protocol Number: 08/152/WRI Start Date*: 2010-03-03
    Sponsor Name:Brighton and Sussex University Hospitals NHS Trust
    Full Title: Better targeting of antidepressants in older people: the influence of age and genetic background on serotonin signalling
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021036 Hyponatraemia LLT
    12.0 10017955 Gastrointestinal haemorrhage LLT
    12.0 10040108 Serotonin syndrome LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001098-94 Sponsor Protocol Number: D12-01 Start Date*: 2014-04-18
    Sponsor Name:GERCOR
    Full Title: A randomized phase II double-blind trial of sunitinib versus placebo in combination with lanreotide in patients with progressive advanced/metastatic midgut carcinoid tumors
    Medical condition: Progressive advanced/metastatic midgut carcinoid tumors
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068118 Metastatic carcinoid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003939-27 Sponsor Protocol Number: 1-10-72-356-12 Start Date*: 2013-02-12
    Sponsor Name:Klaus Krogh
    Full Title: Objective evaluation of the effects of pasireotide on gastrointestinal and colorectal transit times, rectal wall properties, and postprandial response in patients with carcinoid diarrhea
    Medical condition: Patients with neuroendocrine tumors and carcinoid diarrhea
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022975-67 Sponsor Protocol Number: 2010-022975-67 Start Date*: 2011-03-31
    Sponsor Name:AZIENDA U.L.S.S. N.8 DI ASOLO
    Full Title: 68Ga-DOTANOC as a PET tool to diagnose nueroendocrine tumors
    Medical condition: Study of tumor neuroendocrin origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000267-84 Sponsor Protocol Number: CSOM230B2412 Start Date*: 2013-06-07
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continue...
    Medical condition: Cushing’s disease Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    14.1 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) GR (Completed) FR (Completed) PL (Completed) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-003856-30 Sponsor Protocol Number: CSMS995ABE12T Start Date*: 2016-01-28
    Sponsor Name:Cliniques Universitaires Saint Luc
    Full Title: Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syn...
    Medical condition: The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreoti...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005579-10 Sponsor Protocol Number: A-93-52030-325 Start Date*: 2016-02-26
    Sponsor Name:IPSEN S.P.A.
    Full Title: EFFICACY AND SAFETY OF LANREOTIDE ATG 120 MG IN COMBINATION WITH TEMOZOLOMIDE IN SUBJECTS WITH PROGRESSIVE WELL DIFFERENTIATED THORACIC NEUROENDOCRINE TUMORS
    Medical condition: progressive well differentiated thoracic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007282 Carcinoid tumour pulmonary PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037342 Pulmonary carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068115 Metastatic carcinoid tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068118 Metastatic carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005806-38 Sponsor Protocol Number: NO21884 Start Date*: 2009-10-23
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with a...
    Medical condition: PIb: solid malignancy that is metastatic or unresectable PII: C 1: Advanced metastatic renal cell carcinoma C 2: Advanced low- to intermediate grade metastatic or unresectable locoregional pancre...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050076 Metastatic renal carcinoma LLT
    9.1 10065147 Malignant solid tumor LLT
    9.1 10052399 Neuroendocrine tumour LLT
    9.1 10026664 Malignant pancreatic islet neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:53:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA